5 November 2022
Freshfields advises on listing of Giant Biogene Holding Co., Ltd on HKSE
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Richard Wang Lead | Freshfields | Partner | China ECM | Not stated |
| Howie Farn | Freshfields | Partner | Not stated | Not stated |
| Chris Fu | Freshfields | Counsel | Not stated | Not stated |
| Quan Zhou | Freshfields | Senior associate | Not stated | Not stated |
| Xinyu Wang | Freshfields | Associate | Not stated | Not stated |
| Yuwei Tian | Freshfields | Associate | Not stated | Not stated |
| Jianhua Feng | Freshfields | Associate | Not stated | Not stated |
| Zhuolin Li | Freshfields | Associate | Not stated | Not stated |
Stated terms
- Stated value
- HKD 549m (HK$549.4m)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- Giant Biogene Holding Co., Ltd (Issuer)
Goldman Sachs (Asia) L.L.C. (Underwriters)
China International Capital Corporation Hong Kong Securities Limited (Underwriters)